Introduction
============

Randomized trials comparing breast-conservation surgery (BCS) plus adjuvant radiation therapy (RT) with mastectomy alone in early-stage breast cancer have shown no differences in oncologic outcomes \[[@b1-crt-2018-424]-[@b6-crt-2018-424]\]. On the other hand, several recent population-based studies reported that BCS plus RT (BCS+RT) resulted in better oncologic outcomes than mastectomy according to T or N category \[[@b7-crt-2018-424]-[@b11-crt-2018-424]\]. The role of adjuvant RT after mastectomy for pN1 breast cancer is also a controversial issue. Key randomized trials showed better oncologic outcomes in the post-mastectomy RT (PMRT) group compared with the non-PMRT group for breast cancer with nodal metastasis \[[@b12-crt-2018-424],[@b13-crt-2018-424]\]. Subgroup analysis by the Danish Breast Cancer Cooperative Group (DBCG) 82 B&C randomized trial \[[@b13-crt-2018-424]\] and meta-analysis from the Early Breast Cancer Trialists\' Collaborative Group (EBCTCG) \[[@b14-crt-2018-424]\] reported that PMRT had the benefit of local control for subgroups with 1-3 axillary nodal metastases. The National Comprehensive Cancer Network (NCCN) clinical practice guideline recommends strong consideration of PMRT for N1 breast cancer \[[@b15-crt-2018-424]\]. However, the chemotherapeutic regimens of these studies are not the modern one, but mostly the CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) regimen, which is less effective \[[@b16-crt-2018-424],[@b17-crt-2018-424]\].

Anthracycline plus taxane-based (AT) chemotherapy is the currently recommended adjuvant treatment in the breast cancer, especially with nodal metastasis \[[@b15-crt-2018-424]\]. This regimen showed benefits in local control as well as overall survival (OS) comparing with previous chemotherapy regimens \[[@b18-crt-2018-424],[@b19-crt-2018-424]\]. In the era of the AT regimen, the role of PMRT for pN1 disease is still unclear \[[@b20-crt-2018-424],[@b21-crt-2018-424]\]. Therefore, we performed this study to compare oncologic outcomes between BCS+RT and modified radical mastectomy (MRM) alone under the AT regimen and to investigate the role of adjuvant RT in patients with pN1 breast cancer treated by mastectomy.

Materials and Methods
=====================

1. Patients
-----------

We retrospectively reviewed the medical records of 2,011 patients with pathologic N1 breast cancer who underwent BCS+RT or MRM alone at 12 institutions in South Korea between Jan 2006 and Dec 2010.

Information was obtained from medical records regarding pathologic tumor features, including molecular subtype, tumor size, resection margin, lymphovascular invasion (LVI), nuclear grade (NG), histologic grade (HG), number of lymph nodes (LN) with metastasis, and extracapsular extension (ECE). Patients were excluded because of non-AT chemotherapy (n=47), BCS without adjuvant RT (n=37) and PMRT (n=157), and insufficient medical records (n=296). Finally, 1,474 patients were included in the analysis.

2. Treatment
------------

BCS+RT was performed for 1,047 patients (71.0%). The median dose of adjuvant RT on the whole breast was 50 Gy (range, 45 to 50.4 Gy). Tumor bed boost with median dose of 10 Gy (range, 5 to 16 Gy) was applied to 1,026 patients. RT to the supraclavicular fossa with a median dose of 50 Gy (range, 45 to 50.4 Gy) was performed in 320 patients (30.6%), and 37 (3.5%) of them received RT to the internal mammary area with a median dose of 50.4 Gy (range, 45 to 50.4 Gy). RT plans followed the general principles of RT to the whole breast. Median number of axillary LN dissections performed was 16 (range, 1 to 47). Most patients (99.8%) were treated with an AC (adriamycin and cyclophosphamide) plus T (taxane) regimen, while others were administrated the FAC (fluorouracil, adriamycin, and cytoxan) plus T regimen (0.1%) or EC (epirubicin and cyclophosphamide) plus T regimen (0.1%).

MRM alone was performed for 427 patients (29.0%). All patients in the MRM-alone group received a median of 19 axillary LN dissections (range, 2 to 43). AC plus T was administered to most patients (99.8%) in the MRM group. Other patients received the FEC (fluorouracil, epirubicin, and cytoxan) plus T regimen (0.2%). None of this group underwent adjuvant RT.

3. Statistical analysis
-----------------------

OS, disease-free survival (DFS), locoregional failure-free survival (LRFFS), and regional failure-free survival (RFFS) were defined as the interval from surgery to death, cancer recurrence, locoregional recurrence, and regio-nal recurrence, respectively. The chi-square test or Fisher exact test was used to compare patient characteristics and patterns of failure between the BCS+RT and MRM-alone group. The Kaplan-Meier method was used to estimate survival curves. Log-rank tests were performed to compare survival between groups for various variables. Cox regression analysis was chosen for multivariate analysis to determine the independent prognostic factors for outcomes. A two-sided p-value of \< 0.05 was considered statistically significant. Statistical analyses were performed with SPSS ver. 22.0 (IBM Corp., Armonk, NY). Analyses were also performed for subgroups defined according to the number of risk factors identified as significant in multivariate analyses for DFS.

Two-to-one propensity score matching was performed to eliminate imbalances in variables between the two treatment groups. Matching variables were age, menopause status, site, pathology, pathologic T staging, number of LNs with metastasis, LVI, NG, HG, molecular subtype, and ECE. R Statistical Software ver. 3.2.3 (The R foundation for Statistical Analyses, Vienna, Austria) was utilized in propensity score matching.

4. Ethical statement
--------------------

This study was approved by the Institutional Review Board (IRB) of each hospital and performed in accordance with the principles of the Declaration of Helsinki. Each IRB approved a waiver of informed consent.

Results
=======

1. Patient characteristics
--------------------------

The median follow-up duration for the total cohort was 69 months (range, 1 to 114 months). The 5-year rates of OS, DFS, LRFFS, and RFFS of the total cohort were 98.0%, 92.4%, 97.0%, and 97.6%, respectively. Among the total cohort, there were significant differences in age, menopausal status, pathology, pathologic T category, LVI, NG, HG, and ECE between the BCS+RT and MRM-alone groups. After propensity score matching, a total of 1,074 patients (676 in the BCS+RT group and 398 in the MRM-alone group) were included for analysis. The patient characteristics are summarized in [Table 1](#t1-crt-2018-424){ref-type="table"}. The number of dissected LNs were 16 (range, 1 to 42) in BCS+RT group and 18 (range, 2 to 42) in MRM-alone group.

2. Treatment outcome
--------------------

Among 1,074 patients, 92 (8.6%) experienced disease recurrence. The patterns of first failure were not significantly different between the groups ([Table 2](#t2-crt-2018-424){ref-type="table"}). The OS, DFS, LRFFS, and RFFS rates of the BCS+RT group vs. MRM-alone group at 5 years were 98.6% vs. 96.1% (p=0.088), 93.3% vs. 89.7% (p=0.107), 97.6% vs. 95.2% (p=0.254), and 98.3% vs. 95.7% (p=0.102), respectively ([Fig. 1](#f1-crt-2018-424){ref-type="fig"}). On multivariate analysis, luminal A type was identified as an independent prognostic factor associated with better OS ([Table 3](#t3-crt-2018-424){ref-type="table"}). The multivariate analyses revealed that LVI and HG were independent prognosticators associated with DFS and RFFS ([Tables 4](#t4-crt-2018-424){ref-type="table"} and [5](#t5-crt-2018-424){ref-type="table"}).

Three subgroups were determined according to the number of risk factors (positive LVI and HG of III) identified in multivariate analysis for DFS and RFFS: the low risk group (n=346) had no risk factors, the intermediate risk group (n=512) had one risk factor, and the high risk group (n=216) had two risk factors. For the high risk group, BCS+RT showed significantly superior RFFS (99.5% vs. 96.8%, p=0.008) ([Fig. 2](#f2-crt-2018-424){ref-type="fig"}). Although there was also a tendency for BCS+RT to have better DFS for all risk groups, there were no statistically significant differences ([Fig. 2](#f2-crt-2018-424){ref-type="fig"}).

3. Toxicity
-----------

Lymphedema and radiation pneumonitis occurred more frequently in the BCS+RT group than in the MRM-alone group ([Table 6](#t6-crt-2018-424){ref-type="table"}). A total of 8.0% of patients in the MRM-alone group showed lymphedema, while 13.5% of patients presented with lymphedema after BCS+RT (p=0.007). Radiation pneumonitis was present in 1.3% of patients in the BCS+RT group, whereas no patient in the MRM group showed radiation pneumonitis (p=0.031).

Discussion
==========

Randomized trials comparing BCS+RT with mastectomy in early-stage breast cancer have shown comparable oncologic outcomes by long-term follow-up data \[[@b1-crt-2018-424]-[@b6-crt-2018-424]\]. However, several recent population-based studies reported that BCS+RT resulted in superior oncologic outcomes compared to mastectomy \[[@b7-crt-2018-424]-[@b11-crt-2018-424]\]. There are several reasons for this inconsistency in results between historic randomized trials and population-based studies. Those randomized trials were conducted in the 1980s with outdated diagnostic and therapeutic procedures; therefore, local recurrence was much higher \[[@b11-crt-2018-424],[@b22-crt-2018-424]\]. Differences in study designs and patient populations may be additional reasons for inconsistent results between randomized trials and population-based studies \[[@b23-crt-2018-424]\]. The evolution of chemotherapy for early breast cancer may also deviate from the results of historic randomized trials \[[@b18-crt-2018-424],[@b19-crt-2018-424]\]. Therefore, special caution is required in interpreting those randomized trials in current practice. Those population-based studies also have some limitations. The chemotherapy regimens were not standard. In addition, comparisons between treatment modalities were stratified only according to pathologic T or N category, not according to any other histologic or molecular subtype-based characteristics. To our knowledge, the current research is the first study to compare treatment outcomes between BCS+RT and MRM alone under a modern and homogeneous chemotherapy regimen. In addition, the treatment outcomes were compared according to subgroups stratified with various pathological variables for pN1 breast cancer. The inhomogeneity of the demographic and histologic properties was amended by propensity score matching.

The oncologic outcomes were not significantly different between treatment modalities. Among population-based studies, two reported the outcome of the pN1 subgroup. Chen et al. \[[@b8-crt-2018-424]\] used the National Cancer Database and reported the adjusted hazard ratio of mastectomy alone as 1.44 (range, 2.31 to 1.53; p \< 0.001) over BCS+RT in patients with pN1 breast cancer. van Maaren et al. \[[@b11-crt-2018-424]\] analyzed patients selected from the Netherlands Cancer Registry and reported a higher mortality risk rate in the mastectomy compared with the BCS+RT. However, in those studies, mastectomy groups contained higher proportions of patients with large and multi-centric tumors, which are known prognostic factors associated with inferior LRFFS and OS. In addition, information regarding detailed chemotherapy regimen was not clarified, and a considerable proportion of patients treated with chemotherapy were included in the study population. In the modern chemotherapy era, the outcome of mastectomy alone has improved \[[@b18-crt-2018-424],[@b19-crt-2018-424]\]. In particular, some studies have specifically reported that patients with 1-3 positive LNs showed improvement in oncologic outcomes \[[@b20-crt-2018-424],[@b24-crt-2018-424],[@b25-crt-2018-424]\]. Therefore, the results are inconsistent, with the current study showing better outcomes for the mastectomy group than those studies.

The role of PMRT is also a controversial issue for pN1 non-metastatic breast cancer. The DBCG 82 B&C trial and EBCTCG revealed that PMRT reduced mortality rates regardless of the number of LN metastases \[[@b6-crt-2018-424],[@b13-crt-2018-424],[@b14-crt-2018-424]\]. On the other hand, recent retrospective studies showed that addition of PMRT in patients with pN1 breast cancer seems to have no significant impact on oncologic outcomes in the modern chemotherapy era \[[@b20-crt-2018-424],[@b24-crt-2018-424],[@b25-crt-2018-424]\]. In the current study, the benefit of PMRT was not evaluated because patients who received PMRT were excluded from analyses. However, in the high-risk subgroup with LVI and HG 3, which were identified as independent factors associated with poor DFS, the BCS+RT group showed significantly better RFFS than the MRM-alone group. This implied that there might be a role of adjuvant RT in reducing regional recurrence for patients with LVI and HG 3, which are well-known risk factors related to poor locoregional control and LN metastasis \[[@b20-crt-2018-424],[@b26-crt-2018-424]-[@b28-crt-2018-424]\]. Therefore, PMRT is a consideration for patients with LVI and HG III even in the modern chemotherapy era. Further large scale randomized trials with stratification according to detailed risk groups are necessary to identify the role of PMRT in pN1 non-metastatic breast cancer.

There are several limitations in the current study. First, there is inevitable selection bias due to its retrospective nature. Although the propensity score matching method was utilized to balance treatment groups, some variables that were excluded from score matching might have been unevenly distributed. The pathologic data were collected from several different institutions, so bias regarding pathologic information also could not be excluded. Finally, the relatively short follow-up duration of the current study is also a limitation. The median follow-up duration of the total cohort was 69 months, which is not enough to detect late recurrence and treatment-related sequelae \[[@b29-crt-2018-424]\]. Therefore, further follow-up is required to compare long-term oncologic outcomes and adverse effects between treatment groups.

In conclusion, there are no differences in OS, DFS, LRFFS, and RFFS between BCS+RT and MRM alone under the AT chemotherapy regimen for patients with pN1 non-breast cancer. However, BCS+RT showed superior RFFS in patients with LVI and HG III, implying that adjuvant RT potentially has a role in reducing regional recurrence. Therefore, PMRT might be considerable for patients with LVI and HG 3.
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![Survival curves according to treatment group. Overall survival (OS) (A), disease-free survival (DFS) (B), locoregional failure-free survival (LFFS) (C), and regional failure-free survival (RFFS) (D). BCS+RT, breast conserving surgery plus radiation therapy; MRM, modified radical mastectomy.](crt-2018-424f1){#f1-crt-2018-424}

![Subgroup analyses according to risk group for overall survival (OS) (A), disease-free survival (DFS) (B), and regional failure-free survival (RFFS) (C). BCS+RT, breast conserving surgery plus radiation therapy; MRM, modified radical mastectomy; NA, not applicable, ^a)^Hazard ratio was not calculated for RFFS in the low risk group because there was no regional failure in that subgroup.](crt-2018-424f2){#f2-crt-2018-424}

###### 

Baseline characteristics of study patients

  Characteristic              Before matching   After matching                                     
  --------------------------- ----------------- ---------------- ------- ------------ ------------ -------
  **Age (yr)**                47.4±8.6          48.9±9.4         0.004   48.1±8.9     48.7±9.3     0.319
  **Menopausal status**                                                                            
   Premenopause               676 (64.6)        251 (58.8)       0.043   415 (61.4)   238 (59.8)   0.604
   Postmenopause              371 (35.4)        176 (41.2)               261 (38.6)   160 (40.2)   
  **Site**                                                                                         
   Left                       504 (48.1)        217 (50.8)       0.380   330 (48.8)   199 (50.0)   0.732
   Right                      543 (51.9)        210 (49.2)               346 (51.2)   199 (50.0)   
  **Pathology**                                                                                    
   IDC                        984 (94.0)        413 (96.7)       0.044   648 (95.9)   384 (96.5)   0.601
   Non-IDC                    63 (6.0)          14 (3.3)                 28 (4.1)     14 (3.5)     
  **Pathologic T category**                                                                        
   1                          507 (48.4)        160 (37.5)       0.000   280 (41.4)   160 (40.2)   0.897
   2                          532 (50.8)        265 (62.1)               393 (58.1)   236 (59.3)   
   3                          8 (0.8)           2 (0.5)                  3 (0.4)      2 (0.5)      
  **No. of LN metastases**                                                                         
   1                          603 (57.6)        231 (54.1)       0.070   381 (56.4)   218 (54.8)   0.722
   2-3                        444 (42.4)        196 (45.9)               295 (43.6)   180 (45.2)   
  **LN management**                                                                                
   SLNB only                  78 (7.4)          24 (5.6)         0.258   46 (6.8)     22 (5.5)     0.438
   ALND                       969 (92.6)        403 (94.4)               630 (93.2)   376 (94.5)   
  **Positive LN ratio**                                                                            
   ≤ 0.1                      506 (48.3)        233 (54.6)       0.034   338 (50.0)   219 (55.0)   0.101
   \> 0.1                     541 (51.7)        194 (45.4)               338 (50.0)   179 (45.0)   
  **LVI**                                                                                          
   No                         370 (35.3)        273 (63.9)       0.000   397 (58.7)   244 (61.3)   0.068
   Yes                        677 (64.7)        154 (36.1)               279 (41.3)   154 (38.7)   
  **Nuclear grade**                                                                                
   1-2                        599 (57.2)        200 (46.8)       0.000   324 (47.9)   200 (50.3)   0.412
   3                          448 (42.8)        227 (53.2)               352 (52.1)   198 (49.7)   
  **Histologic grade**                                                                             
   I-II                       642 (61.3)        216 (50.6)       0.000   301 (44.5)   185 (46.5)   0.482
   III                        405 (38.7)        211 (49.4)               375 (55.5)   213 (53.5)   
  **Molecular subtype**                                                                            
   Luminal A                  459 (43.8)        192 (45.0)       0.736   375 (55.4)   216 (54.3)   0.736
   Non-luminal A              588 (56.2)        235 (55.0)               301 (44.6)   182 (45.7)   
  **ECE**                                                                                          
   No                         578 (55.2)        267 (62.5)       0.012   382 (56.5)   239 (60.1)   0.247
   Yes                        469 (44.8)        160 (37.5)               294 (43.5)   159 (39.9)   

Values are presented as mean±standard deviation or number (%). BCS, breast conserving surgery; RT, radiation therapy; MRM, modified radical mastectomy; IDC, invasive ductal carcinoma; LN, lymph node; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; LVI, lymphovascular invasion; ECE, extracapsular extension.

###### 

Patterns of the first failure according to field of radiotherapy

  Sites of the first failure                   BCS+RT (n=676)   MRM alone (n=398)   p-value
  -------------------------------------------- ---------------- ------------------- ---------
  **Isolated loco-regional only**              10 (1.5)         6 (1.5)             0.971
   Local only                                  5 (0.7)          2 (0.5)             1.000
   Regional only                               5 (0.7)          4 (1.0)             0.733
  **Distant only**                             28 (4.1)         23 (5.8)            0.223
  **Simultaneous loco-regional and distant**   12 (1.8)         13 (3.3)            0.118
  **Total**                                    50 (7.4)         42 (10.6)           0.074

Values are presented as number (%). BCS, breast conserving surgery; RT, radiation therapy; MRM, modified radical mastectomy.

###### 

Univariate and multivariate analysis (OS)

  Characteristic              Univariate analysis   Multivariate analysis                         
  --------------------------- --------------------- ----------------------- --------------------- -------
  **Age (yr)**                                                                                    
   ≤ 55                       97.7                  0.828                   \-                    \-
   \> 55                      97.5                                          \-                    
  **Menopause status**                                                                            
   Premenopause               98.6                  0.072                   0.592 (0.295-1.190)   0.141
   Postmenopause              96.0                                          \-                    
  **Site**                                                                                        
   Left                       97.3                  0.737                   \-                    \-
   Right                      97.9                                          \-                    
  **Pathology**                                                                                   
   IDC                        97.6                  0.725                   \-                    \-
   Non-IDC                    97.7                                          \-                    
  **Pathologic T category**                                                                       
   1                          97.9                  0.731                   \-                    \-
   2-3                        97.4                                          \-                    
  **No. of LN metastases**                                                                        
   1                          97.8                  0.443                   \-                    \-
   2                          97.4                                          \-                    
  **LVI**                                                                                         
   No                         98.0                  0.342                   \-                    \-
   Yes                        97.2                                          \-                    
  **Nuclear grade**                                                                               
   1-2                        98.9                  0.002                   0.544 (0.174-1.704)   0.296
   3                          96.2                                          \-                    
  **Histologic grade**                                                                            
   I-II                       99.0                  0.004                   0.773 (0.269-2.220)   0.632
   III                        95.9                                          \-                    
  **Molecular subtype**                                                                           
   Luminal A                  99.1                  0.001                   0.327 (0.129-0.825)   0.018
   Non-luminal A              96.3                                          \-                    
  **ECE**                                                                                         
   No                         97.6                  0.771                   \-                    \-
   Yes                        97.7                                          \-                    
  **Modality**                                                                                    
   BCS+RT                     98.6                  0.088                   0.597 (0.297-1.200)   0.147
   MRM alone                  96.1                                          \-                    

OS, overall survival; HR, hazard ratio; CI, confidence interval; IDC, invasive ductal carcinoma; LN, lymph node; LVI, lymphovascular invasion; ECE, extracapsular extension; BCS, breast conserving surgery; RT, radiation therapy; MRM; modified radical mastectomy.

###### 

Univariate and multivariate analysis (DFS)

  Characteristic              Univariate analysis   Multivariate analysis                         
  --------------------------- --------------------- ----------------------- --------------------- -------
  **Age (yr)**                                                                                    
   ≤ 55                       91.9                  0.987                   \-                    \-
   \> 55                      92.3                                          \-                    
  **Menopause status**                                                                            
   Premenopause               92.5                  0.248                   \-                    \-
   Postmenopause              91.0                                          \-                    
  **Site**                                                                                        
   Left                       90.7                  0.171                   1.239 (0.818-1.875)   0.311
   Right                      93.2                                          \-                    
  **Pathology**                                                                                   
   IDC                        91.9                  0.598                   \-                    \-
   Non-IDC                    93.2                                          \-                    
  **Pathologic T category**                                                                       
   1                          95.0                  0.001                   0.665 (0.415-1.064)   0.089
   2-3                        89.6                                          \-                    
  **No. of LN metastases**                                                                        
   1                          93.2                  0.126                   0.823 (0.545-1.244)   0.356
   2-3                        90.4                                          \-                    
  **LVI**                                                                                         
   No                         94.6                  \< 0.001                0.472 (0.304-0.731)   0.001
   Yes                        88.7                                          \-                    
  **Nuclear grade**                                                                               
   1-2                        95.4                  \< 0.001                0.715 (0.389-1.314)   0.280
   3                          88.0                                          \-                    
  **Histologic grade**                                                                            
   I-II                       96.4                  \< 0.001                0.254 (0.134-0.481)   0.001
   III                        86.1                                          \-                    
  **Molecular subtype**                                                                           
   Luminal A                  94.4                  0.024                   0.849 (0.544-1.326)   0.472
   Non-luminal A              90.0                                          \-                    
  **ECE**                                                                                         
   No                         91.8                  0.771                   \-                    \-
   Yes                        92.0                                          \-                    
  **Modality**                                                                                    
   BCS+RT                     93.3                  0.107                   0.702 (0.463-1.065)   0.096
   MRM alone                  89.7                                          \-                    

DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; IDC, invasive ductal carcinoma; LN, lymph node; LVI, lymphovascular invasion; ECE, extracapsular extension; BCS, breast conserving surgery; RT, radiation therapy; MRM; modified radical mastectomy.

###### 

Univariate and multivariate analysis (RFFS)

  Characteristic              Univariate analysis   Multivariate analysis                         
  --------------------------- --------------------- ----------------------- --------------------- ----------
  **Age (yr)**                                                                                    
   ≤ 55                       97.2                  0.915                   \-                    \-
   \> 55                      98.0                                          \-                    
  **Menopause status**                                                                            
   Premenopause               97.3                  0.571                   \-                    \-
   Postmenopause              97.4                                          \-                    
  **Site**                                                                                        
   Left                       96.9                  0.571                   \-                    \-
   Right                      97.8                                          \-                    
  **Pathology**                                                                                   
   IDC                        97.2                  0.218                   \-                    \-
   Non-IDC                    100                                           \-                    
  **Pathologic T category**                                                                       
   1                          98.2                  0.120                   0.890 (0.417-1.900)   0.764
   2-3                        96.7                                          \-                    
  **No. of LN metastases**                                                                        
   1                          97.1                  0.638                   \-                    \-
   2-3                        97.7                                          \-                    
  **LVI**                                                                                         
   No                         98.6                  0.004                   0.340 (0.159-0.726)   0.005
   Yes                        95.9                                          \-                    
  **Nuclear grade**                                                                               
   1-2                        98.8                  0.021                   0.527 (0.205-1.356)   0.184
   3                          95.7                                          \-                    
  **Histologic grade**                                                                            
   I-II                       99.4                  \< 0.001                0.138 (0.047-0.408)   \< 0.001
   III                        94.6                                          \-                    
  **Molecular subtype**                                                                           
   Luminal A                  98.5                  0.193                   0.902 (0.431-1.887)   0.785
   Non-luminal A              96.4                                          \-                    
  **ECE**                                                                                         
   No                         97.3                  0.503                   \-                    \-
   Yes                        97.3                                          \-                    
  **Modality**                                                                                    
   BCS+RT                     98.3                  0.102                   0.523 (0.262-1.044)   0.066
   MRM                        95.7                                          \-                    

RFFS, regional failure-free survival; HR, hazard ratio; CI, confidence interval; IDC, invasive ductal carcinoma; LN, lymph node; LVI, lymphovascular invasion; ECE, extracapsular extension; BCS, breast conserving; RT, radiation therapy; MRM; modified radical mastectomy.

###### 

Treatment-related toxicities

  Morbidity     BCS+RT (n=676)   MRM alone (n=398)   p-value                                     
  ------------- ---------------- ------------------- ----------- ---------- --------- ---------- -------
  Lymphedema    69 (10.2)        22 (3.3)            91 (13.5)   26 (6.5)   6 (1.5)   32 (8.0)   0.007
  Pneumonitis   8 (1.2)          1 (0.1)             9 (1.3)     0          0         0          0.031

Values are presented as number (%). BCS, breast conserving surgery; RT, radiation therapy; MRM, modified radical mastectomy.
